1. Introduction

Blood transfusion is among the most critical therapeutic interventions in modern medicine. It is a procedure in which whole blood or selected blood components are administered intravenously to restore physiological balance—whether by replenishing circulating volume, improving oxygen delivery, or correcting specific hematological deficiencies.

While historically transfusion was viewed simply as “blood replacement,” contemporary practice has evolved into a highly refined discipline grounded in immunohematology, component therapy, and stringent laboratory compatibility testing. This transformation has significantly improved both safety and clinical efficacy.

Modern transfusion medicine integrates several domains of biomedical science:

• Immunohematology, which governs blood group compatibility
• Component processing and storage science, which enables targeted therapy
• Pre-transfusion compatibility testing, ensuring immunological safety
• Recognition and management of transfusion reactions, which remains a critical clinical safeguard

Thus, blood transfusion is no longer a single intervention but a carefully regulated therapeutic system.

2. Blood Group Systems

2.1 The ABO System

The ABO blood group system forms the foundation of transfusion compatibility. It is defined by the presence or absence of A and B antigens on the surface of red blood cells (RBCs), along with naturally occurring antibodies in plasma.
Individuals develop antibodies against the ABO antigens they do not possess. This leads to four primary blood groups:

• Group A: A antigen present; anti-B antibodies in plasma
• Group B: B antigen present; anti-A antibodies in plasma
• Group AB: Both A and B antigens present; no ABO antibodies
• Group O: No A or B antigens; both anti-A and anti-B antibodies present

A key immunological feature of the ABO system is the presence of naturally occurring IgM antibodies. These antibodies are clinically significant because they are:

• Pre-existing without prior transfusion exposure
• Highly efficient at activating complement
• Capable of causing rapid intravascular hemolysis when incompatible blood is transfused

This is why ABO incompatibility is considered the most dangerous and immediate transfusion risk.

2.2 The Rh Blood Group System

The Rh system is primarily determined by the presence or absence of the D antigen. Individuals expressing this antigen are classified as Rh-positive, while those lacking it are Rh-negative.

Unlike the ABO system, Rh antibodies do not exist naturally. They develop only after exposure to Rh-positive blood through transfusion or fetomaternal hemorrhage during pregnancy.

These anti-D antibodies are predominantly IgG type, which is clinically important because IgG:

• Can cross the placenta
• Mediates extravascular hemolysis
• Plays a central role in hemolytic disease of the fetus and newborn

Thus, Rh incompatibility is not typically an immediate reaction but becomes clinically significant upon sensitization.

3. Immunological Mechanism of Transfusion Reactions

3.1 ABO Incompatibility

When ABO-incompatible blood is transfused, pre-existing recipient IgM antibodies rapidly bind to donor RBC antigens. This interaction activates the complement cascade, leading to immediate destruction of red cells within the bloodstream.

The result is acute intravascular hemolysis, a catastrophic process characterized by the release of free hemoglobin and activation of inflammatory and coagulation pathways. Clinically, this can progress rapidly to shock, renal failure, and disseminated intravascular coagulation (DIC).

3.2 Rh Incompatibility

Rh reactions differ fundamentally in timing and severity. The primary exposure often leads to sensitization without severe hemolysis. However, subsequent exposure triggers a rapid IgG-mediated immune response.

Because IgG antibodies act mainly through extravascular mechanisms, hemolysis tends to be slower and less dramatic than ABO incompatibility, though clinically significant in repeated transfusions or pregnancy.

4. Universal Donor and Recipient Concept

4.1 Packed Red Cell Transfusion

In emergency transfusion practice, O Rh-negative blood is often described as the “universal donor” for red cells. This is because it lacks A, B, and D antigens, minimizing immediate immune reactions.

However, modern immunohematology recognizes that this designation is an oversimplification. True immunological compatibility is more complex due to:

• Minor blood group antigens (e.g., Kell, Kidd, Duffy systems)
• Risk of alloimmunization after repeated exposure

Therefore, universal donor status is a practical emergency concept rather than a biologically absolute one.

4.2 Universal Recipient Concept

Individuals with AB Rh-positive blood may receive red cells from any ABO group without immediate incompatibility reactions. However, this does not eliminate the need for careful Rh matching and minor antigen consideration, particularly in chronically transfused patients.

In modern practice, the idea of a “universal recipient” is similarly limited and primarily theoretical.

5. Pre-Transfusion Testing

Safe transfusion depends on rigorous laboratory evaluation.

5.1 Blood Grouping

Determination of ABO and Rh status is the foundational step for both donor and recipient. Errors at this stage can lead to fatal outcomes.

5.2 Antibody Screening

This test identifies unexpected alloantibodies in the recipient’s serum that may react with minor red cell antigens. It is essential for preventing delayed hemolytic reactions.

5.3 Crossmatching

Crossmatching serves as the final compatibility check between donor red cells and recipient serum. The major crossmatch is the most clinically significant, ensuring that recipient antibodies do not react with donor RBCs.

The indirect Coombs test enhances detection of clinically relevant IgG antibodies, increasing the sensitivity of pre-transfusion screening.

6. The Coombs (Antiglobulin) Test

The Coombs test is a cornerstone of immunohematology and exists in two forms.
The Direct Coombs Test detects antibodies already bound to red blood cells within the patient’s circulation. It is widely used in autoimmune hemolytic anemia, hemolytic disease of the newborn, and transfusion reactions.

The Indirect Coombs Test, in contrast, identifies free circulating antibodies in serum that have the potential to react with transfused RBCs. It is routinely used in pre-transfusion testing and antenatal screening.

7. Hemolytic Transfusion Reactions

7.1 Pathophysiology

Acute hemolytic transfusion reactions occur when incompatible donor RBCs are destroyed by recipient antibodies. This leads to complement activation, intravascular hemolysis, and systemic inflammatory injury.

The downstream effects include hemoglobinemia, hemoglobinuria, endothelial damage, and activation of the coagulation cascade, which may culminate in DIC.

7.2 Clinical Features

Early manifestations are often nonspecific and include fever, chills, back pain, and anxiety. As the reaction progresses, hypotension, shock, acute kidney injury, and bleeding tendencies may develop.

7.3 Management

Immediate discontinuation of transfusion is critical. Supportive management includes maintaining intravenous access with saline, stabilizing hemodynamics, and monitoring renal function closely.

8. Hemolytic Disease of the Newborn (HDFN)

8.1 Pathogenesis

HDFN occurs when an Rh-negative mother becomes sensitized to Rh-positive fetal red cells. Maternal IgG antibodies formed during sensitization cross the placenta in subsequent pregnancies and destroy fetal RBCs.

8.2 Clinical Features

The severity ranges from mild anemia and jaundice to hydrops fetalis and kernicterus, depending on the extent of hemolysis and bilirubin accumulation.

8.3 Prevention

The condition is largely preventable through administration of anti-D immunoglobulin to Rh-negative mothers, which prevents sensitization by neutralizing fetal Rh-positive cells.

9. Blood Components and Component Therapy

Modern transfusion practice prioritizes the use of specific blood components rather than whole blood.

Packed red blood cells are used primarily to restore oxygen-carrying capacity in anemia or hemorrhage.

Fresh frozen plasma provides a complete spectrum of coagulation factors and is indicated in coagulopathies such as liver disease and DIC.

Cryoprecipitate is enriched in fibrinogen and key clotting factors and is used in conditions such as hemophilia A and hypofibrinogenemia.

Platelet concentrates are essential in preventing or treating bleeding in thrombocytopenic states.

Plasma-derived proteins such as albumin and immunoglobulins serve specialized roles in volume expansion and passive immunity.

10. Plasma Substitutes

In situations where blood products are not required, plasma substitutes such as crystalloids and colloids are used to maintain intravascular volume. Although they do not carry oxygen or clotting factors, they are valuable in resuscitation protocols.

11. Blood Storage and Preservation

Blood preservation relies on anticoagulant solutions such as CPDA-1, which maintain cellular viability during storage.

Red blood cells are stored at 2–6°C, while plasma products are frozen at sub-zero temperatures to preserve clotting factors.

During storage, biochemical and structural changes—known as storage lesions—occur, including ATP depletion, potassium leakage, and reduced red cell deformability, all of which may affect post-transfusion efficacy.

12. Transfusion Reactions

Transfusion reactions are broadly categorized into immune and non-immune mechanisms.

Immune-mediated reactions include acute hemolysis, febrile non-hemolytic reactions, allergic responses, and anaphylaxis.

Non-immune complications include transfusion-related acute lung injury (TRALI), circulatory overload (TACO), and iron overload in chronically transfused patients.

13. TRALI and TACO

TRALI is a severe immune-mediated pulmonary complication characterized by acute lung injury and non-cardiogenic pulmonary edema, and it remains one of the leading causes of transfusion-related mortality.

TACO, in contrast, results from fluid overload and is most commonly seen in elderly patients or those with cardiac dysfunction.

14. Clinical Transfusion Strategy

Modern transfusion practice emphasizes restrictive strategies, often using hemoglobin thresholds around 7–8 g/dL in stable patients. This approach minimizes unnecessary exposure to donor blood while maintaining clinical safety.

Whole blood transfusion is now largely reserved for massive hemorrhage scenarios.

15. Blood Safety and Screening

All donated blood undergoes mandatory screening for transfusion-transmissible infections, including HIV, hepatitis B and C, syphilis, and malaria in endemic regions. This ensures the highest possible safety for recipients.

16. Massive Transfusion Protocol

In severe trauma or hemorrhage, massive transfusion protocols are activated to restore hemodynamic stability. These protocols emphasize balanced replacement of red cells, plasma, and platelets to prevent dilutional coagulopathy and improve survival outcomes.

17. Conclusion

Blood transfusion today represents a sophisticated intersection of immunology, laboratory medicine, and clinical therapeutics. Its safety and effectiveness depend on precise compatibility testing, meticulous handling of blood components, and a deep understanding of immune mechanisms.

Modern transfusion medicine has shifted from a generalized replacement strategy to a targeted, component-based approach, significantly reducing risk while improving patient outcomes. Understanding its principles is therefore essential for safe and effective clinical practice.